- Previous Close
56.68 - Open
56.68 - Bid 57.47 x 800
- Ask 57.48 x 800
- Day's Range
56.52 - 57.66 - 52 Week Range
39.35 - 61.08 - Volume
2,848,079 - Avg. Volume
10,474,688 - Market Cap (intraday)
115.941B - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
-- - EPS (TTM)
-3.58 - Earnings Date Feb 6, 2025
- Forward Dividend & Yield 2.48 (4.38%)
- Ex-Dividend Date Jan 3, 2025
- 1y Target Est
60.91
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
www.bms.com34,100
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BMY
View MorePerformance Overview: BMY
Trailing total returns as of 1/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BMY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BMY
View MoreValuation Measures
Market Cap
114.96B
Enterprise Value
158.26B
Trailing P/E
--
Forward P/E
7.98
PEG Ratio (5yr expected)
1.95
Price/Sales (ttm)
2.42
Price/Book (mrq)
6.71
Enterprise Value/Revenue
3.34
Enterprise Value/EBITDA
31.21
Financial Highlights
Profitability and Income Statement
Profit Margin
-15.30%
Return on Assets (ttm)
6.07%
Return on Equity (ttm)
-31.33%
Revenue (ttm)
47.44B
Net Income Avi to Common (ttm)
-7.26B
Diluted EPS (ttm)
-3.58
Balance Sheet and Cash Flow
Total Cash (mrq)
8.09B
Total Debt/Equity (mrq)
299.05%
Levered Free Cash Flow (ttm)
17.52B